Drug Search Results
More Filters [+]

LY-3451838

Alternative Names: ly-3451838, ly 3451838, ly3451838
Latest Update: 2023-11-28
Latest Update Note: Clinical Trial Update

Product Description

Eli Lilly is developing LY-3451838 as a treatment for migraines. (Sourced from: https://trials.lilly.com/en-US/trial/283602)

Mechanisms of Action: PACAP38 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous,Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LY-3451838

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Migraine Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

J1H-MC-LAJB

P2

Completed

Migraine Disorders

2022-11-09

Recent News Events